OTC$PTN

Palatin Technologies Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Announced fourth quarter and fiscal year ended 2023 financial results and provided corporate update.

Palatin Technologies reported its Q4 2023 financial results, with Vyleesi's net product revenue increasing by 47% and prescriptions dispensed increasing by 16% over the prior quarter. The Phase 3 PL9643 clinical study is fully enrolled, with interim analysis showing statistically significant positive effects on multiple endpoints.

  • PL9643 Phase 3 MELODY-1 clinical study patient enrollment completed.
  • Interim analysis of PL9643 data demonstrated statistically significant positive effects on multiple endpoints for both signs and symptoms, with excellent patient safety and tolerability.
  • Vyleesi's net product revenue increased 47% over the prior quarter.
  • Total prescriptions dispensed increased 16% over the prior quarter.

Headline financials

Total Revenue

$1.76M

Previous: $771K+128.6%
EPS (adj)

-$0.91

Previous: -$1.34+32.1%
Capital Expenditures

$52.4K

No prior period
Free Cash Flow

-$9.66M

No prior period
Net Income

-$10.7M

Previous: -$12.8M+16.4%
Operating Income

-$12.6M

Previous: -$13.9M+9.4%
Gross Profit

$1.8M

No prior period
Cash & Equivalents

$11M

Previous: $29.9M-63.2%
Total Assets

$41.2M

No prior period
Stock-Based Comp

$222K

No prior period

Revenue & EPS history

Palatin Technologies · Revenue · Quarterly

$1.76M

Q4 2023+128.6%vs Q4 2022
Beat estimate in 4 of 10 quarters(40%)
ActualEstimate

Forward guidance

Palatin expects several key milestones in the coming quarters, including data readouts and study initiations.

Tailwinds

  • Topline Data Expected Late 4Q Calendar Year 2023
  • Interim Analysis Targeted for 1Q Calendar Year 2024
  • Topline Results Currently Expected First Half Calendar Year 2024
  • Phase 2 clinical study in PDE5i non-responder ED patients is currently expected to commence late fourth quarter calendar year 2023.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

-2.4%

Avg return

Earnings day

-0.6%

Avg return

5 days after

-2.5%

Avg return

30 days after

31%

20 / 64 earnings

Positive

+36.4%

Q3 2026

Best reaction

-27.1%

Q2 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026+1.2%+29.2%+18.2%
Q1 2026+0.0%+27.8%+152.3%
Q3 2026+36.4%+9.1%-9.1%
Q3 2025+22.2%+55.6%+11.1%
Q2 2025+7.1%+4.0%-20.2%
Q1 2025-21.5%-21.8%-26.1%
Q4 2024-8.3%-1.1%+39.3%
Q3 2024-15.4%-15.4%-24.5%
Q2 2024-27.1%-21.7%-62.8%
Q1 2024-1.0%-2.5%+31.3%
Q4 2023-8.5%+19.7%+13.3%
Q3 2023-5.8%-3.1%-13.9%
Q2 2023-8.8%-2.2%-18.0%
Q1 2023-9.0%-5.8%-25.7%
Q4 2022-19.5%-27.7%-43.6%
Q3 2022-7.7%-10.3%-28.2%
Q2 2022+5.0%+0.0%+2.5%
Q1 2022-2.5%-10.0%+35.0%
Q4 2021-6.4%-8.5%-12.8%
Q3 2021+9.8%+13.4%+10.4%
Q2 2021-19.5%-23.9%-33.6%
Q1 2021+7.3%+2.4%+4.9%
Q4 2020+0.0%-4.2%-20.8%
Q3 2020-2.2%-2.2%+30.4%
Q2 2020-14.1%-18.3%-39.4%
Q1 2020-4.9%-2.5%-1.2%
Q4 2019+7.1%+3.0%-16.2%
Q3 2019+2.2%+7.9%-10.1%
Q2 2019+2.7%+6.8%+36.5%
Q1 2019-10.8%-17.2%-21.5%
Q4 2018-3.8%-2.9%-14.3%
Q3 2018-4.6%-7.6%-22.9%
Q2 2018+5.6%+7.8%+6.7%
Q1 2018+0.0%+8.7%+10.0%
Q4 2017-6.1%+0.0%+15.2%
Q3 2017-12.8%-10.6%-25.5%
Q2 2017-6.8%-11.4%-22.7%
Q1 2017-5.5%-5.5%+1.8%
Q4 2016-1.8%+16.1%-3.6%
Q3 2016-3.6%
Q2 2016+2.0%
Q1 2016-7.7%
Q4 2015-8.5%
Q3 2015+1.1%
Q2 2015+23.0%
Q1 2015+4.0%
Q4 2014-5.0%
Q3 2014-2.6%
Q2 2014-7.0%
Q1 2014+15.3%
Q4 2013-7.0%
Q3 2013+1.6%
Q2 2013-5.9%
Q1 2013+7.9%
Q4 2012-6.3%
Q4 2010-6.3%
Q3 2011+5.0%
Q3 2012+5.0%
Q2 2012-5.9%
Q2 2011-5.9%
Q1 2012-3.8%
Q1 2011-3.8%
Q4 2011-3.8%
Q3 2010-9.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro